Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet

Allergo Journal International - Tập 32 Số 1 - Trang 10-17
Ludger Klimek1, Randolf Brehler2, Ingrid Casper1, Felix Klimek1, Jan Hagemann3, Mandy Cuevas4, Karl‐Christian Bergmann5
1Center for Rhinology and Allergology, Wiesbaden, Germany
2Clinic for Skin Diseases, Münster University Hospital, Muenster, Germany
3Department of Otorhinolaryngology, Mainz University Medical Center, Mainz, Germany
4Clinic and Polyclinic for Otorhinolaryngology, Carl Gustav Carus University Hospital, TU Dresden, Dresden, Germany
5Institute for Allergy Research, Charité—Universitätsmedizin Berlin, Berlin, Germany

Tóm tắt

AbstractBackgroundA perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life of patients and is associated with a high socioeconomic burden. The most common symptoms of allergic rhinitis include a runny nose and nasal congestion, sneezing, itching of nose, mouth and/or throat, and/or ocular symptoms. Affected patients often develop allergic bronchial asthma. Therapy options for allergic rhinitis include allergen avoidance, symptomatic treatment, and allergen immunotherapy. Allergen immunotherapy is the only disease-modifying treatment that can permanently alleviate the symptoms of allergic rhinitis. In July 2021, a new sublingual mite tablet was approved in Germany.MethodsThis review summarizes clinical studies on the 300 IR (index of reactivity) mite tablet in adolescents and adults with house dust mite-associated allergic rhinitis and presents the results.ResultsIn the phase II and phase III studies considered here, different dosages of the mite tablet were investigated. The 300 IR mite tablet showed the best benefit–risk profile and has been approved in Europe, Japan, South Korea, Australia, and New Zealand for the treatment of house dust mite-associated allergic rhinitis.ConclusionAllergen immunotherapy with the 300 IR mite tablet is an effective treatment that relieves allergic symptoms, reduces the need for symptomatic medication, and improves the quality of life in both adults and adolescents with house dust mite-associated allergic rhinitis. At the same time, treatment with the 300 IR mite tablet is well tolerated. Mild to moderate reactions at the application site subside after a few days.

Từ khóa


Tài liệu tham khảo

Batard T, Baron-Bodo V, Martelet A, Le Mignon M, Lemoine P, Jain K, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71:220–9.

Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015;136:38–48.

Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines. 2014;13:1463–73.

Aggarwal P, Senthilkumaran S. Dust mite allergy. Treasure Island: StatPearls; 2022.

Braido F, Arcadipane F, Marugo F, Hayashi M, Pawankar R. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014;14:168–76.

Brehler R, Klimek L, Kopp MV, Virchow JC. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int. 2013;110:148–58.

Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–76.

Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106:S12–S6.

Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69:1275–9.

Linneberg A, Henrik Nielsen N, Frølund L, Madsen F, Dirksen A, Jørgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen allergy study. Allergy. 2002;57:1048–52.

Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372:1049–57.

Klimek L, Bergmann K‑C, Casper I, Klimek F, Hagemann J, Cuevas M. Karenzmaßnahmen bei Milbenallergie – ein Update. Allergo J Int. 2022.

Calderón MA, Kleine-Tebbe J, Linneberg A, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3:843–55.

Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American academy of allergy, asthma & immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288–1296.e3.

Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.

Stallergenes. Orylmyte-Fachinformation. 2021. https://www.stallergenesgreer.de/sites/default/files/documents/1714_Fachinfo_Orylmyte_11.2021.pdf. Accessed 13 Oct 2022.

Batard T, Hrabina A, Bi XZ, Chabre H, Lemoine P, Couret M‑N, et al. Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol. 2006;140:295–305.

Demoly P, Corren J, Creticos P, De Blay F, Gevaert P, Hellings P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2020;147:1020–1030.e10.

Baron-Bodo V, Batard T, Nguyen H, Fréreux M, Horiot S, Harwanegg C, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy. 2012;42:1510–8.

Potapova E, Bordas-Le Floch V, Schlederer T, Vrtala S, Huang H‑J, Canonica GW, et al. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. Allergy. 2022;77:3084–95.

Weghofer M, Grote M, Resch Y, Casset A, Kneidinger M, Kopec J, et al. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol. 2013;190:3059–67.

Celi G, Brusca I, Scala E, Villalta D, Pastorello E, Farioli L, et al. House dust mite allergy in Italy-Diagnostic and clinical relevance of Der p 23 (and of minor allergens): A real-life, multicenter study. Allergy. 2019;74:1787–9.

Jiménez-Feijoo R, Pascal M, Moya R, Riggioni C, Domínguez O, Lózano J, et al. Molecular diagnosis in house dust mite-allergic patients suggests that der p 23 is clinically relevant in asthmatic children. J Investig Allergol Clin Immunol. 2019;30:127–32.

Posa D, Hofmaier S, Arasi S, Matricardi PM. Natural evolution of IgE responses to mite allergens and relationship to progression of allergic disease: a review. Curr Allergy Asthma Rep. 2017;17:28.

Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2016;139:541–549.e8.

Mascarell L, Batard T, Cuiné JF, Nony E. The bioavailability of allergens in allergy tablets depends on several factors. Int Arch Allergy Immunol. 2018;175:252–3.

Roux M, Devillier P, Yang WH, Montagut A, Abiteboul K, Viatte A, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. J Allergy Clin Immunol. 2016;138:451–458.e5.

Bergmann K‑C, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133:1608–1614.e6.

Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2016;72:435–43.

Okamoto Y, Fujieda S, Okano M, Hida H, Kakudo S, Masuyama K. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population. Pediatr Allergy Immunol. 2018;30:66–73.

Pfaar O, Kleine-Tebbe J, Demoly P, Bahbah F. Clinical relevance of treatment with 300 IR house dust mite SLIT tablet. [abstract P1.10]. Allergo J Int. 2021;30:215.

Demoly P, Meziane L, LeGall M, André C, Melac M. Safety and tolerability of house dust mite tablets in sublingual immunotherapy. J Allergy Clin Immunol. 2008;121:128.

Demoly P, Le Gall M, Roux M, Zeldin RK. Safety and tolerability of high doses of sublingual tablet of house dust mite allergen extracts in subjects with house dust mite-associated respiratory allergy. Allergy. 2015;70(Suppl.101):452

Roux M, Patel P, Viatte A, Cognet-Sicé J, Zeldin RK. Safety of high doses of sub-lingual tablets of house dust mite allergen extracts in adolescents with allergic rhinitis. Allergy. 2014;69(Suppl.99):613

Pfaar O, Demoly P, Creticos P, De Blay F, Gevaert PGEU, Karagiannis E, et al. Reduction in rescue medication use in patients treated with the 300 IR house dust mite SLIT tablet. 2020. [abstract no. 1866]. Allergy 2020;75(Suppl. 109):102–3.

Worm M, Bergmann K-C, Daghildjian K, Yan K. Safety review of 300 IR house dust mite tablet from pooled data of clinical trials and post marketing experience [abstract no. 1869]. Allergy 2020;75(Suppl.109):103

Okamoto Y, Ishii K, Kato M, Hayashi H, Hata T. Safety and effectiveness of the 300 IR sublingual house dust mite allergen immunotherapy tablet: 2‑year interim analysis of a specified drug-use survey. Immunotherapy. 2021;13:1333–43.

Calderón MA, Simons FER, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302–11.

Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1:228–41.

Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18–27.

Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007;119:780–91.

Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2:2.

Devillier P, Brüning H, Bergmann K‑C. Determination of the minimally important difference in a nasal symptom score in house dust mite allergy. Allergy. 2019;74:2191–8.

Thông tin
Thông tin xuất bản

Allergo Journal International

Tập 32 Số 1

10-17

Thông tin tác giả